NC
PVLA

NewSquare Capital’s Palvella Therapeutics PVLA Stock Holding History

NewSquare Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$18 – 918
2023
Q2 		$18 Hold
1
– – ﹤0.01% 838
2023
Q1 		$107 Hold
1
– – ﹤0.01% 821
2022
Q4 		$114 Buy
+1
New +$80 ﹤0.01% 767

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NewSquare Capital's PVLA Position: Q3 2023 in Review

NewSquare Capital sold out of Palvella Therapeutics (PVLA) in Q3 2023, closing a stake of 1 share — an estimated $18 sold.

NewSquare Capital first reported a position in PVLA in Q4 2022 and held it in 3 quarters. The position peaked at $114 in Q4 2022. 43 funds tracked by Wall St. Rank hold PVLA as of Q3 2023.

  • NewSquare Capital reported no remaining Palvella Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 1 Palvella Therapeutics share in Q3 2023, an estimated $18.
  • NewSquare Capital first reported a position in Palvella Therapeutics in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Palvella Therapeutics position peaked at $114 in Q4 2022.
  • 43 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.